# Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

> **NCT00322491** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 49 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Multiple Myeloma

## Interventions

- **DRUG:** G-CSF Plus Plerixafor

## Key facts

- **NCT ID:** NCT00322491
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2006-06
- **Final completion:** 2006-06
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2014-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00322491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00322491, "Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00322491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*